Shares of fourteen drug makers rose by 0.99% to 6.16% on reports global pharma firms are scouting for acquiring Indian drug makers, as generic penetration in the developed market is expected to increase in the coming years.
At a time when global multinational drug makers are slashing their workforces to reduce costs, their Indian counterparts are on a hiring spree.
Patent expiry will be a major avenue of growth for the Indian pharmaceutical industry as products worth $235 billion are going off patent within horizon of five years (from 2009 to 2014).
Finally,the government has fulfilled the demand of pharmaceutical industry to meet its long-standing demand of trained manpower by giving in principle approval for setting up of six National Institutes of Pharmaceutical Education and Research (NIPER)
New laws in Kansas and Missouri, prescribe a methamphetamine cook shouldn
Introduction of pentavalent vaccine in the National Immunisation Programme, was kept pending for quite a while, is likely to take off soon.
Retail pharmacy management software business was sold by Arcadia for $2.2 million, cash, to an undisclosed pharmacy benefits management company.
FDBE with The Guild of Healthcare Pharmacists (GHP) and the UK Clinical Pharmacy Association (UKCPA), are pleased to announce the 2010 FDBE/GHP/UKCPA Information Technology Award.
On Tuesday, drug maker GlaxoSmithKline (GSK), established a US $600 million plant in Singapore that is stated to begin producing anti-pneumonia vaccine in 2011.
Lack of adequate isotopes will be an important subject of discussion for the experts convening at the Society of Nuclear Medicine (SNM) meeting in Toronto on the coming weekend.
Ahmedabad-based Cadila Pharmaceuticals on Saturday said it is expecting a revenue of INR 100 crore from the sale of its patented combination drug, Policap, which it expects to launch by the middle of next month.
Indian pharmaceutical companies are reworking their strategies for Europe to cope with the intense pressure on drug prices because of changing trends in the key market.
Ranbaxy Laboratories announced that its new anti-malarial combination drug is now undergoing final stage of development. In its press-release, the company said that the drug is targeted at patients in developing countries with the aim of significantly improving upon the conventional options available for the treatment of P falciparum malaria.
